Table I.
Risks of uveitis in ustekinumab and tumour necrosis factor α inhibitor-treated groups with multivariable Cox proportional hazards regression and inverse probability of treatment weighting (IPTW)
| Number | Event | Person-years | IR* | HR (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |||||
| Before IPTW | |||||||||
| TNF-α inhibitor | 1,746 | 35 | 3,446.6 | 10.16 | 1 [Reference]** | 1 | 1 | 1 | 1 |
| Ustekinumab | 2,467 | 13 | 5,551.5 | 2.34 | 0.232 (0.123–0.439) | 0.226 (0.119–0.428) | 0.223 (0.118–0.424) | 0.222 (0.117–0.421) | 0.223 (0.117–0.424) |
| After IPTW | |||||||||
| TNF-α inhibitor | 1,784.6 | 35.4 | 3,481.4 | 10.18 | 1 | ||||
| Ustekinumab | 2,464.6 | 12.6 | 5,515.7 | 2.28 | 0.223 (0.113–0.414) | ||||
*
Per 1,000 person-years.
**
TNFi is the reference.
Model 1: non-adjusted. Model 2: Adjusted for sex and age. Model 3: Adjusted for sex, age, diabetes mellitus, hypertension, and dyslipidaemia. Model 4: Adjusted for sex, age, diabetes mellitus, hypertension, dyslipidaemia, and malignancy. Model 5: Adjusted for sex, age, diabetes mellitus, hypertension, dyslipidaemia, malignancy, and psoriatic arthritis.
IR: incidence rate; HR: hazard ratio; CI: confidence interval.